Amundi Index Solutions - Amundi EURO STOXX 50 UCITS ETF-D EUR
Amundi Index Solutions - Amundi EURO STOXX 50 UCITS ETF-D EUR (CD5.PA) Stock Competitors & Peer Comparison
See (CD5.PA) competitors and their performances in Stock Market.
Peer Comparison Table: Asset Management - Global Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CD5.PA | €97.50 | -0.14% | 4.9B | 18.57 | €5.25 | +2.38% |
| IWDD.AS | €8.02 | +0.41% | 142.4B | 25.03 | €0.32 | +1.13% |
| CSPX.AS | €698.74 | +0.18% | 128.3B | N/A | N/A | N/A |
| IWDA.AS | €123.38 | +0.17% | 121.8B | N/A | N/A | N/A |
| VUSA.AS | €123.21 | +0.15% | 70.8B | N/A | N/A | +0.87% |
| VWRL.AS | €158.82 | +0.20% | 57B | N/A | N/A | +1.25% |
| SP5H.PA | €365.95 | +0.41% | 26.1B | 28.54 | €12.82 | +0.90% |
| SP5C.PA | €471.35 | +0.16% | 26B | 28.56 | €16.51 | N/A |
| ISFA.AS | €11.83 | -0.30% | 18.2B | N/A | N/A | +2.87% |
| IUSA.AS | €64.79 | +0.17% | 18.1B | N/A | N/A | +0.86% |
Stock Comparison
CD5.PA vs IWDD.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IWDD.AS has a market cap of 142.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while IWDD.AS trades at €8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IWDD.AS's P/E ratio is 25.03. In terms of profitability, CD5.PA's ROE is N/A, compared to IWDD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IWDD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IWDD.AS's competition here
CD5.PA vs CSPX.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CSPX.AS has a market cap of 128.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while CSPX.AS trades at €698.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CSPX.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to CSPX.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CSPX.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CSPX.AS's competition here
CD5.PA vs IWDA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IWDA.AS has a market cap of 121.8B. Regarding current trading prices, CD5.PA is priced at €97.50, while IWDA.AS trades at €123.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IWDA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to IWDA.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to IWDA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IWDA.AS's competition here
CD5.PA vs VUSA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, VUSA.AS has a market cap of 70.8B. Regarding current trading prices, CD5.PA is priced at €97.50, while VUSA.AS trades at €123.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas VUSA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to VUSA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to VUSA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check VUSA.AS's competition here
CD5.PA vs VWRL.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, VWRL.AS has a market cap of 57B. Regarding current trading prices, CD5.PA is priced at €97.50, while VWRL.AS trades at €158.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas VWRL.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to VWRL.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to VWRL.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check VWRL.AS's competition here
CD5.PA vs SP5H.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, SP5H.PA has a market cap of 26.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while SP5H.PA trades at €365.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas SP5H.PA's P/E ratio is 28.54. In terms of profitability, CD5.PA's ROE is N/A, compared to SP5H.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SP5H.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SP5H.PA's competition here
CD5.PA vs SP5C.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, SP5C.PA has a market cap of 26B. Regarding current trading prices, CD5.PA is priced at €97.50, while SP5C.PA trades at €471.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas SP5C.PA's P/E ratio is 28.56. In terms of profitability, CD5.PA's ROE is N/A, compared to SP5C.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SP5C.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SP5C.PA's competition here
CD5.PA vs ISFA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ISFA.AS has a market cap of 18.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while ISFA.AS trades at €11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ISFA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to ISFA.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to ISFA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ISFA.AS's competition here
CD5.PA vs IUSA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IUSA.AS has a market cap of 18.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while IUSA.AS trades at €64.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IUSA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to IUSA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IUSA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IUSA.AS's competition here
CD5.PA vs MEUD.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, MEUD.PA has a market cap of 15.6B. Regarding current trading prices, CD5.PA is priced at €97.50, while MEUD.PA trades at €307.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas MEUD.PA's P/E ratio is 18.44. In terms of profitability, CD5.PA's ROE is N/A, compared to MEUD.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to MEUD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MEUD.PA's competition here
CD5.PA vs I500.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, I500.AS has a market cap of 15B. Regarding current trading prices, CD5.PA is priced at €97.50, while I500.AS trades at €12.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas I500.AS's P/E ratio is 28.60. In terms of profitability, CD5.PA's ROE is N/A, compared to I500.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to I500.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check I500.AS's competition here
CD5.PA vs I50D.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, I50D.AS has a market cap of 14.8B. Regarding current trading prices, CD5.PA is priced at €97.50, while I50D.AS trades at €8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas I50D.AS's P/E ratio is 28.55. In terms of profitability, CD5.PA's ROE is N/A, compared to I50D.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to I50D.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check I50D.AS's competition here
CD5.PA vs IMEU.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IMEU.AS has a market cap of 10.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while IMEU.AS trades at €38.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IMEU.AS's P/E ratio is 18.55. In terms of profitability, CD5.PA's ROE is N/A, compared to IMEU.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IMEU.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IMEU.AS's competition here
CD5.PA vs WLDHC.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, WLDHC.PA has a market cap of 10.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while WLDHC.PA trades at €16.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas WLDHC.PA's P/E ratio is 25.10. In terms of profitability, CD5.PA's ROE is N/A, compared to WLDHC.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to WLDHC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WLDHC.PA's competition here
CD5.PA vs WLDH.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, WLDH.PA has a market cap of 10.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while WLDH.PA trades at €262.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas WLDH.PA's P/E ratio is 25.18. In terms of profitability, CD5.PA's ROE is N/A, compared to WLDH.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to WLDH.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WLDH.PA's competition here
CD5.PA vs WLD.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, WLD.PA has a market cap of 10.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while WLD.PA trades at €415.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas WLD.PA's P/E ratio is 25.26. In terms of profitability, CD5.PA's ROE is N/A, compared to WLD.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to WLD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WLD.PA's competition here
CD5.PA vs CEUU.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CEUU.AS has a market cap of 9.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while CEUU.AS trades at €12.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CEUU.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to CEUU.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CEUU.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CEUU.AS's competition here
CD5.PA vs AEME.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, AEME.PA has a market cap of 9.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while AEME.PA trades at €102.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas AEME.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to AEME.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to AEME.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check AEME.PA's competition here
CD5.PA vs IEMM.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IEMM.AS has a market cap of 8.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while IEMM.AS trades at €58.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IEMM.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to IEMM.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to IEMM.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IEMM.AS's competition here
CD5.PA vs SJPD.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, SJPD.AS has a market cap of 8.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while SJPD.AS trades at €8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas SJPD.AS's P/E ratio is 18.87. In terms of profitability, CD5.PA's ROE is N/A, compared to SJPD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to SJPD.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check SJPD.AS's competition here
CD5.PA vs IEMA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IEMA.AS has a market cap of 7.8B. Regarding current trading prices, CD5.PA is priced at €97.50, while IEMA.AS trades at €56.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IEMA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to IEMA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IEMA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IEMA.AS's competition here
CD5.PA vs IWRD.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IWRD.AS has a market cap of 7.8B. Regarding current trading prices, CD5.PA is priced at €97.50, while IWRD.AS trades at €89.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IWRD.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to IWRD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IWRD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IWRD.AS's competition here
CD5.PA vs SJPE.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, SJPE.AS has a market cap of 7.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while SJPE.AS trades at €14.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas SJPE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to SJPE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SJPE.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SJPE.AS's competition here
CD5.PA vs UST.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, UST.PA has a market cap of 7.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while UST.PA trades at €105.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas UST.PA's P/E ratio is 36.20. In terms of profitability, CD5.PA's ROE is N/A, compared to UST.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to UST.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check UST.PA's competition here
CD5.PA vs VEUR.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, VEUR.AS has a market cap of 6.9B. Regarding current trading prices, CD5.PA is priced at €97.50, while VEUR.AS trades at €48.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas VEUR.AS's P/E ratio is 18.51. In terms of profitability, CD5.PA's ROE is N/A, compared to VEUR.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to VEUR.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check VEUR.AS's competition here
CD5.PA vs AUEM.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, AUEM.PA has a market cap of 6.8B. Regarding current trading prices, CD5.PA is priced at €97.50, while AUEM.PA trades at €9.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas AUEM.PA's P/E ratio is 20.36. In terms of profitability, CD5.PA's ROE is N/A, compared to AUEM.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to AUEM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check AUEM.PA's competition here
CD5.PA vs CW8.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CW8.PA has a market cap of 6.6B. Regarding current trading prices, CD5.PA is priced at €97.50, while CW8.PA trades at €672.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CW8.PA's P/E ratio is 25.26. In terms of profitability, CD5.PA's ROE is N/A, compared to CW8.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CW8.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CW8.PA's competition here
CD5.PA vs IJPA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IJPA.AS has a market cap of 6.6B. Regarding current trading prices, CD5.PA is priced at €97.50, while IJPA.AS trades at €68.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IJPA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to IJPA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to IJPA.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check IJPA.AS's competition here
CD5.PA vs EWLD.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EWLD.PA has a market cap of 6.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while EWLD.PA trades at €39.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EWLD.PA's P/E ratio is 25.16. In terms of profitability, CD5.PA's ROE is N/A, compared to EWLD.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to EWLD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EWLD.PA's competition here
CD5.PA vs EXCH.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EXCH.AS has a market cap of 5.9B. Regarding current trading prices, CD5.PA is priced at €97.50, while EXCH.AS trades at €9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EXCH.AS's P/E ratio is 21.64. In terms of profitability, CD5.PA's ROE is N/A, compared to EXCH.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to EXCH.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check EXCH.AS's competition here
CD5.PA vs AEEM.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, AEEM.PA has a market cap of 5.8B. Regarding current trading prices, CD5.PA is priced at €97.50, while AEEM.PA trades at €7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas AEEM.PA's P/E ratio is 19.20. In terms of profitability, CD5.PA's ROE is N/A, compared to AEEM.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to AEEM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check AEEM.PA's competition here
CD5.PA vs C50U.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, C50U.PA has a market cap of 5.7B. Regarding current trading prices, CD5.PA is priced at €97.50, while C50U.PA trades at €189.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas C50U.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to C50U.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to C50U.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check C50U.PA's competition here
CD5.PA vs USA.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, USA.PA has a market cap of 5.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while USA.PA trades at €596.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas USA.PA's P/E ratio is 29.69. In terms of profitability, CD5.PA's ROE is N/A, compared to USA.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to USA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check USA.PA's competition here
CD5.PA vs USAC.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, USAC.PA has a market cap of 5.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while USAC.PA trades at €652.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas USAC.PA's P/E ratio is 29.28. In terms of profitability, CD5.PA's ROE is N/A, compared to USAC.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to USAC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check USAC.PA's competition here
CD5.PA vs EUEA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EUEA.AS has a market cap of 5.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while EUEA.AS trades at €61.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EUEA.AS's P/E ratio is 18.68. In terms of profitability, CD5.PA's ROE is N/A, compared to EUEA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA and EUEA.AS have similar daily volatility (0.92).Check EUEA.AS's competition here
CD5.PA vs S500.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, S500.PA has a market cap of 5.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while S500.PA trades at €188.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas S500.PA's P/E ratio is 29.04. In terms of profitability, CD5.PA's ROE is N/A, compared to S500.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to S500.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check S500.PA's competition here
CD5.PA vs S500H.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, S500H.PA has a market cap of 5.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while S500H.PA trades at €106.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas S500H.PA's P/E ratio is 29.30. In terms of profitability, CD5.PA's ROE is N/A, compared to S500H.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to S500H.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check S500H.PA's competition here
CD5.PA vs SEMD.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, SEMD.AS has a market cap of 5.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while SEMD.AS trades at €7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas SEMD.AS's P/E ratio is 19.20. In terms of profitability, CD5.PA's ROE is N/A, compared to SEMD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SEMD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SEMD.AS's competition here
CD5.PA vs SEMI.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, SEMI.AS has a market cap of 4.9B. Regarding current trading prices, CD5.PA is priced at €97.50, while SEMI.AS trades at €21.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas SEMI.AS's P/E ratio is 48.59. In terms of profitability, CD5.PA's ROE is N/A, compared to SEMI.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to SEMI.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check SEMI.AS's competition here
CD5.PA vs C50.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, C50.PA has a market cap of 4.9B. Regarding current trading prices, CD5.PA is priced at €97.50, while C50.PA trades at €162.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas C50.PA's P/E ratio is 18.60. In terms of profitability, CD5.PA's ROE is N/A, compared to C50.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to C50.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check C50.PA's competition here
CD5.PA vs MSE.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, MSE.PA has a market cap of 4.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while MSE.PA trades at €68.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas MSE.PA's P/E ratio is 18.54. In terms of profitability, CD5.PA's ROE is N/A, compared to MSE.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to MSE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MSE.PA's competition here
CD5.PA vs VERX.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, VERX.AS has a market cap of 4.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while VERX.AS trades at €49.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas VERX.AS's P/E ratio is 18.57. In terms of profitability, CD5.PA's ROE is N/A, compared to VERX.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to VERX.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check VERX.AS's competition here
CD5.PA vs SRIL.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, SRIL.AS has a market cap of 4.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while SRIL.AS trades at €13.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas SRIL.AS's P/E ratio is 25.42. In terms of profitability, CD5.PA's ROE is N/A, compared to SRIL.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SRIL.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SRIL.AS's competition here
CD5.PA vs CACC.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CACC.PA has a market cap of 4.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while CACC.PA trades at €41.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CACC.PA's P/E ratio is 17.42. In terms of profitability, CD5.PA's ROE is N/A, compared to CACC.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to CACC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check CACC.PA's competition here
CD5.PA vs CAC.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CAC.PA has a market cap of 4.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while CAC.PA trades at €82.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CAC.PA's P/E ratio is 17.46. In terms of profitability, CD5.PA's ROE is N/A, compared to CAC.PA's ROE of N/A. Regarding short-term risk, CD5.PA is less volatile compared to CAC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check CAC.PA's competition here
CD5.PA vs ROBA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ROBA.AS has a market cap of 4.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while ROBA.AS trades at €90.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ROBA.AS's P/E ratio is 11.99. In terms of profitability, CD5.PA's ROE is N/A, compared to ROBA.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to ROBA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ROBA.AS's competition here
CD5.PA vs EEUE.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EEUE.PA has a market cap of 4B. Regarding current trading prices, CD5.PA is priced at €97.50, while EEUE.PA trades at €19.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EEUE.PA's P/E ratio is 18.84. In terms of profitability, CD5.PA's ROE is N/A, compared to EEUE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to EEUE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EEUE.PA's competition here
CD5.PA vs INRA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, INRA.AS has a market cap of 3.7B. Regarding current trading prices, CD5.PA is priced at €97.50, while INRA.AS trades at €34.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas INRA.AS's P/E ratio is 25.24. In terms of profitability, CD5.PA's ROE is N/A, compared to INRA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to INRA.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check INRA.AS's competition here
CD5.PA vs IDSE.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IDSE.AS has a market cap of 3.6B. Regarding current trading prices, CD5.PA is priced at €97.50, while IDSE.AS trades at €150.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IDSE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to IDSE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IDSE.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IDSE.AS's competition here
CD5.PA vs BNKE.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, BNKE.PA has a market cap of 3.6B. Regarding current trading prices, CD5.PA is priced at €97.50, while BNKE.PA trades at €343.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas BNKE.PA's P/E ratio is 11.20. In terms of profitability, CD5.PA's ROE is N/A, compared to BNKE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to BNKE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check BNKE.PA's competition here
CD5.PA vs WESE.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, WESE.PA has a market cap of 3.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while WESE.PA trades at €84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas WESE.PA's P/E ratio is 26.61. In terms of profitability, CD5.PA's ROE is N/A, compared to WESE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to WESE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WESE.PA's competition here
CD5.PA vs ISED.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ISED.AS has a market cap of 3.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while ISED.AS trades at €7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ISED.AS's P/E ratio is 21.08. In terms of profitability, CD5.PA's ROE is N/A, compared to ISED.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to ISED.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ISED.AS's competition here
CD5.PA vs ICHD.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ICHD.AS has a market cap of 3.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while ICHD.AS trades at €4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ICHD.AS's P/E ratio is 12.42. In terms of profitability, CD5.PA's ROE is N/A, compared to ICHD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ICHD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ICHD.AS's competition here
CD5.PA vs ESE.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ESE.PA has a market cap of 3.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while ESE.PA trades at €32.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ESE.PA's P/E ratio is 28.70. In terms of profitability, CD5.PA's ROE is N/A, compared to ESE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ESE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ESE.PA's competition here
CD5.PA vs ICHN.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ICHN.AS has a market cap of 3.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while ICHN.AS trades at €5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ICHN.AS's P/E ratio is 12.43. In terms of profitability, CD5.PA's ROE is N/A, compared to ICHN.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to ICHN.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check ICHN.AS's competition here
CD5.PA vs INRE.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, INRE.PA has a market cap of 3.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while INRE.PA trades at €29.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas INRE.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to INRE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to INRE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check INRE.PA's competition here
CD5.PA vs TNOW.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, TNOW.PA has a market cap of 3.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while TNOW.PA trades at €1,187.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas TNOW.PA's P/E ratio is 41.13. In terms of profitability, CD5.PA's ROE is N/A, compared to TNOW.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to TNOW.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check TNOW.PA's competition here
CD5.PA vs EPAB.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EPAB.PA has a market cap of 2.7B. Regarding current trading prices, CD5.PA is priced at €97.50, while EPAB.PA trades at €40.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EPAB.PA's P/E ratio is 17.44. In terms of profitability, CD5.PA's ROE is N/A, compared to EPAB.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to EPAB.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EPAB.PA's competition here
CD5.PA vs AASI.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, AASI.PA has a market cap of 2.7B. Regarding current trading prices, CD5.PA is priced at €97.50, while AASI.PA trades at €59.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas AASI.PA's P/E ratio is 21.30. In terms of profitability, CD5.PA's ROE is N/A, compared to AASI.PA's ROE of N/A. Regarding short-term risk, CD5.PA is less volatile compared to AASI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check AASI.PA's competition here
CD5.PA vs BNK.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, BNK.PA has a market cap of 2.7B. Regarding current trading prices, CD5.PA is priced at €97.50, while BNK.PA trades at €64.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas BNK.PA's P/E ratio is 11.70. In terms of profitability, CD5.PA's ROE is N/A, compared to BNK.PA's ROE of N/A. Regarding short-term risk, CD5.PA is less volatile compared to BNK.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check BNK.PA's competition here
CD5.PA vs CMUD.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CMUD.PA has a market cap of 2.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while CMUD.PA trades at €82.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CMUD.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to CMUD.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to CMUD.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check CMUD.PA's competition here
CD5.PA vs CTEC.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CTEC.AS has a market cap of 2.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while CTEC.AS trades at €5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CTEC.AS's P/E ratio is 19.84. In terms of profitability, CD5.PA's ROE is N/A, compared to CTEC.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to CTEC.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check CTEC.AS's competition here
CD5.PA vs ACWI.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ACWI.PA has a market cap of 2.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while ACWI.PA trades at €593.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ACWI.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to ACWI.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to ACWI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ACWI.PA's competition here
CD5.PA vs EXA1.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EXA1.AS has a market cap of 2.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while EXA1.AS trades at €18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EXA1.AS's P/E ratio is 11.19. In terms of profitability, CD5.PA's ROE is N/A, compared to EXA1.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to EXA1.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check EXA1.AS's competition here
CD5.PA vs IUHE.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IUHE.AS has a market cap of 2.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while IUHE.AS trades at €6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IUHE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to IUHE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to IUHE.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check IUHE.AS's competition here
CD5.PA vs MPAB.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, MPAB.AS has a market cap of 2B. Regarding current trading prices, CD5.PA is priced at €97.50, while MPAB.AS trades at €6.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas MPAB.AS's P/E ratio is 18.89. In terms of profitability, CD5.PA's ROE is N/A, compared to MPAB.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to MPAB.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MPAB.AS's competition here
CD5.PA vs EMPA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EMPA.AS has a market cap of 2B. Regarding current trading prices, CD5.PA is priced at €97.50, while EMPA.AS trades at €7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EMPA.AS's P/E ratio is 18.83. In terms of profitability, CD5.PA's ROE is N/A, compared to EMPA.AS's ROE of N/A. Regarding short-term risk, CD5.PA is less volatile compared to EMPA.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check EMPA.AS's competition here
CD5.PA vs EMRG.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EMRG.PA has a market cap of 1.9B. Regarding current trading prices, CD5.PA is priced at €97.50, while EMRG.PA trades at €91.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EMRG.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to EMRG.PA's ROE of N/A. Regarding short-term risk, CD5.PA is less volatile compared to EMRG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check EMRG.PA's competition here
CD5.PA vs H2OA.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, H2OA.AS has a market cap of 1.9B. Regarding current trading prices, CD5.PA is priced at €97.50, while H2OA.AS trades at €23.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas H2OA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to H2OA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to H2OA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check H2OA.AS's competition here
CD5.PA vs EEMU.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EEMU.PA has a market cap of 1.9B. Regarding current trading prices, CD5.PA is priced at €97.50, while EEMU.PA trades at €19.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EEMU.PA's P/E ratio is 18.32. In terms of profitability, CD5.PA's ROE is N/A, compared to EEMU.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to EEMU.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EEMU.PA's competition here
CD5.PA vs MUSD.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, MUSD.AS has a market cap of 1.9B. Regarding current trading prices, CD5.PA is priced at €97.50, while MUSD.AS trades at €10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas MUSD.AS's P/E ratio is 28.55. In terms of profitability, CD5.PA's ROE is N/A, compared to MUSD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to MUSD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MUSD.AS's competition here
CD5.PA vs EUSRI.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, EUSRI.PA has a market cap of 1.6B. Regarding current trading prices, CD5.PA is priced at €97.50, while EUSRI.PA trades at €89.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas EUSRI.PA's P/E ratio is 20.89. In terms of profitability, CD5.PA's ROE is N/A, compared to EUSRI.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to EUSRI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EUSRI.PA's competition here
CD5.PA vs C6E.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, C6E.PA has a market cap of 1.6B. Regarding current trading prices, CD5.PA is priced at €97.50, while C6E.PA trades at €157.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas C6E.PA's P/E ratio is 18.28. In terms of profitability, CD5.PA's ROE is N/A, compared to C6E.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to C6E.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check C6E.PA's competition here
CD5.PA vs WAT.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, WAT.PA has a market cap of 1.6B. Regarding current trading prices, CD5.PA is priced at €97.50, while WAT.PA trades at €66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas WAT.PA's P/E ratio is 23.56. In terms of profitability, CD5.PA's ROE is N/A, compared to WAT.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to WAT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WAT.PA's competition here
CD5.PA vs ALAT.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ALAT.PA has a market cap of 1.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while ALAT.PA trades at €20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ALAT.PA's P/E ratio is 12.42. In terms of profitability, CD5.PA's ROE is N/A, compared to ALAT.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to ALAT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check ALAT.PA's competition here
CD5.PA vs CJ1.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CJ1.PA has a market cap of 1.5B. Regarding current trading prices, CD5.PA is priced at €97.50, while CJ1.PA trades at €343.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CJ1.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to CJ1.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CJ1.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CJ1.PA's competition here
CD5.PA vs LWCR.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, LWCR.PA has a market cap of 1.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while LWCR.PA trades at €611.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas LWCR.PA's P/E ratio is 26.20. In terms of profitability, CD5.PA's ROE is N/A, compared to LWCR.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to LWCR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check LWCR.PA's competition here
CD5.PA vs IFFI.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, IFFI.AS has a market cap of 1.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while IFFI.AS trades at €11.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas IFFI.AS's P/E ratio is 20.86. In terms of profitability, CD5.PA's ROE is N/A, compared to IFFI.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IFFI.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IFFI.AS's competition here
CD5.PA vs CG1.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, CG1.PA has a market cap of 1.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while CG1.PA trades at €444.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas CG1.PA's P/E ratio is 18.75. In terms of profitability, CD5.PA's ROE is N/A, compared to CG1.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CG1.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CG1.PA's competition here
CD5.PA vs WITS.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, WITS.AS has a market cap of 1.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while WITS.AS trades at €20.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas WITS.AS's P/E ratio is 40.60. In terms of profitability, CD5.PA's ROE is N/A, compared to WITS.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to WITS.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check WITS.AS's competition here
CD5.PA vs ESEH.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ESEH.PA has a market cap of 1.4B. Regarding current trading prices, CD5.PA is priced at €97.50, while ESEH.PA trades at €24.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ESEH.PA's P/E ratio is 28.40. In terms of profitability, CD5.PA's ROE is N/A, compared to ESEH.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ESEH.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ESEH.PA's competition here
CD5.PA vs DAX.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, DAX.PA has a market cap of 1.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while DAX.PA trades at €228.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas DAX.PA's P/E ratio is 18.73. In terms of profitability, CD5.PA's ROE is N/A, compared to DAX.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to DAX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check DAX.PA's competition here
CD5.PA vs MFED.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, MFED.PA has a market cap of 1.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while MFED.PA trades at €359.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas MFED.PA's P/E ratio is 18.13. In terms of profitability, CD5.PA's ROE is N/A, compared to MFED.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to MFED.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MFED.PA's competition here
CD5.PA vs PABW.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, PABW.PA has a market cap of 1.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while PABW.PA trades at €90.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas PABW.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to PABW.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to PABW.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check PABW.PA's competition here
CD5.PA vs ETZD.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ETZD.PA has a market cap of 1.3B. Regarding current trading prices, CD5.PA is priced at €97.50, while ETZD.PA trades at €17.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ETZD.PA's P/E ratio is 17.97. In terms of profitability, CD5.PA's ROE is N/A, compared to ETZD.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to ETZD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ETZD.PA's competition here
CD5.PA vs TSWE.AS Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, TSWE.AS has a market cap of 1.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while TSWE.AS trades at €41.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas TSWE.AS's P/E ratio is 20.57. In terms of profitability, CD5.PA's ROE is N/A, compared to TSWE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to TSWE.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check TSWE.AS's competition here
CD5.PA vs PSPH.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, PSPH.PA has a market cap of 1.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while PSPH.PA trades at €26.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas PSPH.PA's P/E ratio is 28.54. In terms of profitability, CD5.PA's ROE is N/A, compared to PSPH.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to PSPH.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check PSPH.PA's competition here
CD5.PA vs PSP5.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, PSP5.PA has a market cap of 1.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while PSP5.PA trades at €56.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas PSP5.PA's P/E ratio is 28.56. In terms of profitability, CD5.PA's ROE is N/A, compared to PSP5.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to PSP5.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check PSP5.PA's competition here
CD5.PA vs P500H.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, P500H.PA has a market cap of 1.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while P500H.PA trades at €47.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas P500H.PA's P/E ratio is 27.82. In terms of profitability, CD5.PA's ROE is N/A, compared to P500H.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to P500H.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check P500H.PA's competition here
CD5.PA vs LEM.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, LEM.PA has a market cap of 1.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while LEM.PA trades at €19.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas LEM.PA's P/E ratio is 18.99. In terms of profitability, CD5.PA's ROE is N/A, compared to LEM.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to LEM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check LEM.PA's competition here
CD5.PA vs PE500.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, PE500.PA has a market cap of 1.2B. Regarding current trading prices, CD5.PA is priced at €97.50, while PE500.PA trades at €53.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas PE500.PA's P/E ratio is 27.88. In terms of profitability, CD5.PA's ROE is N/A, compared to PE500.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to PE500.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check PE500.PA's competition here
CD5.PA vs NRJ.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, NRJ.PA has a market cap of 1.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while NRJ.PA trades at €46.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas NRJ.PA's P/E ratio is 27.19. In terms of profitability, CD5.PA's ROE is N/A, compared to NRJ.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to NRJ.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check NRJ.PA's competition here
CD5.PA vs MFEC.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, MFEC.PA has a market cap of 1.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while MFEC.PA trades at €18.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas MFEC.PA's P/E ratio is 18.32. In terms of profitability, CD5.PA's ROE is N/A, compared to MFEC.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to MFEC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MFEC.PA's competition here
CD5.PA vs MFE.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, MFE.PA has a market cap of 1.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while MFE.PA trades at €80.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas MFE.PA's P/E ratio is 18.27. In terms of profitability, CD5.PA's ROE is N/A, compared to MFE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to MFE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MFE.PA's competition here
CD5.PA vs RS2U.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, RS2U.PA has a market cap of 1.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while RS2U.PA trades at €435.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas RS2U.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is N/A, compared to RS2U.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to RS2U.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check RS2U.PA's competition here
CD5.PA vs ESGH.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ESGH.PA has a market cap of 1.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while ESGH.PA trades at €29.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ESGH.PA's P/E ratio is 20.49. In terms of profitability, CD5.PA's ROE is N/A, compared to ESGH.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ESGH.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ESGH.PA's competition here
CD5.PA vs ESGE.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, ESGE.PA has a market cap of 1.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while ESGE.PA trades at €40.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas ESGE.PA's P/E ratio is 20.45. In terms of profitability, CD5.PA's ROE is N/A, compared to ESGE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ESGE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ESGE.PA's competition here
CD5.PA vs GOAI.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, GOAI.PA has a market cap of 1.1B. Regarding current trading prices, CD5.PA is priced at €97.50, while GOAI.PA trades at €140.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas GOAI.PA's P/E ratio is 40.86. In terms of profitability, CD5.PA's ROE is N/A, compared to GOAI.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to GOAI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check GOAI.PA's competition here
CD5.PA vs PUST.PA Comparison May 2026
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 4.9B. In comparison, PUST.PA has a market cap of 990.3M. Regarding current trading prices, CD5.PA is priced at €97.50, while PUST.PA trades at €104.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 18.57, whereas PUST.PA's P/E ratio is 36.43. In terms of profitability, CD5.PA's ROE is N/A, compared to PUST.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to PUST.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check PUST.PA's competition here